Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. Consolidated revenue for 2008 was EUR689.6 million, operating income was EUR144.7 million and net income was EUR100.4 million.
For more information about Recordati please visit http://www.recordati.com.
References
1. Phatak H et al Atherosclerosis 2009;202:225-33
2. Ferrières J et al Arch Cardiovasc Dis 2008;101:557-63
3. García Ruiz FJ et al Pharmacoeconomics 2004;22 Suppl 3:1-12
4. Hermans MP et al Acta Cardiol 2009;64:177-85
5. Foley KA, Simpson RJ Jr, Crouse JR III, et al., Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events Am J Cardiol. 2003;92:79-81
6. Phatak H, Wentworth C, Sazonov V, et al., Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general practice Atherosclerosis 2009;202:225-33
CONTACT: Laura Anderson, +44(0)207-861-3033, l.anderson@bellpottingerhealth.com
